Watch a Yale Cancer Center Grand Rounds lecture exploring comprehensive insights into Hepatocellular Carcinoma (HCC), from screening protocols to treatment strategies. Learn about this global health challenge that stands as a leading cause of liver-related and cancer-related mortality. Discover how liver cancer surveillance saves lives and understand the evolving at-risk populations as liver disease patterns change. Examine the limitations of ultrasound screening and explore the potential of MRI for early detection, including details about the nine-year PREMIUM study comparing ultrasound and MRI effectiveness. Delve into various biomarker options for early detection, the promise of liquid biopsy, and the complexities of distinguishing oncogenic pathways from normal liver repair processes. Understand HCC's unique position among cancers, explore the linear progression of treatment approaches, and learn about locoregional therapy options for early and intermediate stage disease. Dr. Tamar Taddei emphasizes the importance of multidisciplinary care and advocates for moving toward personalized treatment approaches beyond current clinical characteristic-based paradigms.
Hepatocellular Carcinoma - From Screening to Treatment: Current Practice, Pearls, and Puzzles
Yale Cancer Center via YouTube
Overview
Syllabus
Intro
Objectives
HCC is a global health problem.
HCC is a leading cause of liver-related and cancer-related mortality.
Liver cancer surveillance saves lives.
At risk populations are changing with the changing natural history of liver disease.
How do we identify opportunities for directed education and outreach?
Ultrasound lacks sensitivity for early stage detection of HCC.
Could we move the needle on early detection?
Cirrhosis is highly prevalent and MRI is readily available at the VA.
Will earlier detection with aMRI actually result in a cancer-related mortality benefit?
PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM)
PREMIUM is a nine-year study.
Biomarkers for early detection vary in performance and readiness
Liquid biopsy is encouraging, but requires cross validation and better precision
Teasing out oncogenic pathways from hepatic injury and repair is complex (and not linear).
HCC is clinically complicated, because it is unique among cancers.
Treatment of HCC has followed a linear pathway from early to advanced disease.
Multidisciplinary care is essential.
There are many options for locoregional therapy in early and intermediate stage disease
The current paradigm is based on clinical characteristics
We need to collectively strive for a personalized approach.
Key take aways
Taught by
Yale Cancer Center
